Product Datasheet

PepPool: SARS-CoV-2 Omicron BA.1 (S1), scanning
Product code:3636-1

Contents:SARS-CoV-2 (Omicron BA.1) S1 scanning pool contains 168 peptides fromthe human SARS-CoV-2 virus variant Omicron (B.1.1.529), lineage BA.1.
The peptides are 15-mers overlapping with 11 amino acids, covering theS1 domain of the spike protein. The peptide pool contains mutations:
A67V, _DELTA_69-70, T95I, G142D, _DELTA_143-145, _DELTA_211, L212I,
ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N,T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G,H655Y, N679K, P681H of Omicron BA.1 spike S1.
The pool is supplied in two vials: Pool 1: SARS-CoV-2 (Omicron BA.1) S1
peptides 1-84 (84 peptides) and pool 2: SARS-CoV-2 (Omicron BA.1) S1
peptides 85-168 (84 peptides). The mean purity of the synthetic peptides
is 80%.

Applications:

The peptide pool is recommended for enumeration of cytokine secreting
T cells specific for the SARS-CoV-2 Omicron BA.1 S1 protein with ELISpot/FluoroSpot. The peptide pool has been validated using human PBMC fromCOVID-19 convalescent individuals and vaccinated individuals.

Instructions:

Sterile handling is recommended. Pool 1 and pool 2 can either be used
separately or mixed. If used separately, dissolve the lyophilized peptide
pools by addition of 40 μl DMSO to each vial, then add 85 μl PBS. If mixed,
first add 40 μl DMSO to pool 1 and transfer the solution intopool 2, then add 85 μl PBS. The concentration of these stock solutions are
200 μg/ml of each peptide. Aliquote the pools and store at -20°C or below.
Dilute the stock solution 1:100 in cell culture medium to obtain
2 μg/ml of each peptide in the cell culture. Use the peptide pool in ELISpot
and FluoroSpot assay for stimulation of 250,000 cells per well. Use thediluted peptide solution fresh.

Storage:

Shipped at ambient temperature. Store frozen at -20°C or below uponreceipt. After reconstitution, store aliquotes at -20°C or below. We
recommend the aliquots not be refrozen after initial use.

Quantity:

Two vials (pool 1+2), 25 μg of each peptide

Note; for research use only.
Mabtech shall not be liable for the use or handling of the product or forconsequential, special, indirect or incidental damages therefrom.
Mabtech AB (Head Office)SwedenTel: +46 8 716 27 00
mabtech@mabtech.com

Updated on 2022-11-22

Mabtech, Inc.
USA
Tel: +1 513 871-4500
mabtech.usa@mabtech.com

CERTIFIED
ISO 9001

CERTIFIED
ISO 13485

Quality management systems

Medical devices
Quality management systems

Developed and manufactured by MABTECH AB, Sweden,
whose quality management system complies with thestandards ISO 9001:2015 & ISO 13485:2016.

www.mabtech.com

Peptides included in PepPool: SARS-CoV-2 Omicron BA.1 (S1), scanning
Peptide1234567891011121314151617181920212223242526272829303132333435363738394041424344454647484950515253545556

Sequence
Pool 1 (1-84)

MFVFLVLLPLVSSQC
LVLLPLVSSQCVNLTPLVSSQCVNLTTRTQSQCVNLTTRTQLPPANLTTRTQLPPAYTNSRTQLPPAYTNSFTRG
PPAYTNSFTRGVYYPTNSFTRGVYYPDKVFTRGVYYPDKVFRSSVYYPDKVFRSSVLHSTKVFRSSVLHSTQDLF
SSVLHSTQDLFLPFFHSTQDLFLPFFSNVTDLFLPFFSNVTWFHVPFFSNVTWFHVISGTNVTWFHVISGTNGTKFHVISGTNGTKRFDN
SGTNGTKRFDNPVLPGTKRFDNPVLPFNDGFDNPVLPFNDGVYFAVLPFNDGVYFASIEKNDGVYFASIEKSNIIYFASIEKSNIIRGWIIEKSNIIRGWIFGTTNIIRGWIFGTTLDSKGWIFGTTLDSKTQSLGTTLDSKTQSLLIVNDSKTQSLLIVNNATNQSLLIVNNATNVVIKIVNNATNVVIKVCEF
ATNVVIKVCEFQFCNVIKVCEFQFCNDPFLCEFQFCNDPFLDHKNFCNDPFLDHKNNKSWPFLDHKNNKSWMESEHKNNKSWMESEFRVYKSWMESEFRVYSSANESEFRVYSSANNCTF
RVYSSANNCTFEYVSSANNCTFEYVSQPFLCTFEYVSQPFLMDLEYVSQPFLMDLEGKQG
PFLMDLEGKQGNFKNDLEGKQGNFKNLREFKQGNFKNLREFVFKNFKNLREFVFKNIDGYREFVFKNIDGYFKIYFKNIDGYFKIYSKHTDGYFKIYSKHTPIIVKIYSKHTPIIVREPEKHTPIIVREPEDLPQIIVREPEDLPQGFSAEPEDLPQGFSALEPLLPQGFSALEPLVDLPFSALEPLVDLPIGINEPLVDLPIGINITRF

PeptideSequence

PeptideSequence

57DLPIGINITRFQTLLGINITRFQTLLALHRTRFQTLLALHRSYLTTLLALHRSYLTPGDSLHRSYLTPGDSSSGWYLTPGDSSSGWTAGAGDSSSGWTAGAAAYY
SGWTAGAAAYYVGYLAGAAAYYVGYLQPRTAYYVGYLQPRTFLLKGYLQPRTFLLKYNEN
PRTFLLKYNENGTIT
LLKYNENGTITDAVDNENGTITDAVDCALDTITDAVDCALDPLSEAVDCALDPLSETKCTALDPLSETKCTLKSFLSETKCTLKSFTVEKKCTLKSFTVEKGIYQKSFTVEKGIYQTSNFVEKGIYQTSNFRVQPIYQTSNFRVQPTESISNFRVQPTESIVRFPVQPTESIVRFPNITNESIVRFPNITNLCPF
RFPNITNLCPFDEVFITNLCPFDEVFNATRCPFDEVFNATRFASV112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168

NYNYLYRLFRKSNLK

58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84

85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111

Pool 2 (85-168)

EVFNATRFASVYAWNATRFASVYAWNRKRIASVYAWNRKRISNCVAWNRKRISNCVADYSKRISNCVADYSVLYNNCVADYSVLYNLAPFDYSVLYNLAPFFTFKLYNLAPFFTFKCYGVAPFFTFKCYGVSPTKTFKCYGVSPTKLNDLYGVSPTKLNDLCFTNPTKLNDLCFTNVYAD
NDLCFTNVYADSFVIFTNVYADSFVIRGDEYADSFVIRGDEVRQIFVIRGDEVRQIAPGQGDEVRQIAPGQTGNIRQIAPGQTGNIADYNPGQTGNIADYNYKLPGNIADYNYKLPDDFTDYNYKLPDDFTGCVIKLPDDFTGCVIAWNSDFTGCVIAWNSNKLDCVIAWNSNKLDSKVSWNSNKLDSKVSGNYNKLDSKVSGNYNYLYRKVSGNYNYLYRLFRKLYRLFRKSNLKPFERFRKSNLKPFERDISTNLKPFERDISTEIYQFERDISTEIYQAGNKISTEIYQAGNKPCNG
IYQAGNKPCNGVAGFGNKPCNGVAGFNCYFCNGVAGFNCYFPLRSAGFNCYFPLRSYSFRCYFPLRSYSFRPTYGLRSYSFRPTYGVGHQSFRPTYGVGHQPYRVTYGVGHQPYRVVVLSGHQPYRVVVLSFELLYRVVVLSFELLHAPAVLSFELLHAPATVCG
ELLHAPATVCGPKKSAPATVCGPKKSTNLVVCGPKKSTNLVKNKCKKSTNLVKNKCVNFNNLVKNKCVNFNFNGLNKCVNFNFNGLKGTG
NFNFNGLKGTGVLTENGLKGTGVLTESNKKGTGVLTESNKKFLPFLTESNKKFLPFQQFG
NKKFLPFQQFGRDIALPFQQFGRDIADTTD
QFGRDIADTTDAVRDDIADTTDAVRDPQTLTTDAVRDPQTLEILD
VRDPQTLEILDITPC
QTLEILDITPCSFGGILDITPCSFGGVSVITPCSFGGVSVITPGTFGGVSVITPGTNTSNSVITPGTNTSNQVAVPGTNTSNQVAVLYQG
TSNQVAVLYQGVNCTVAVLYQGVNCTEVPVYQGVNCTEVPVAIHANCTEVPVAIHADQLTVPVAIHADQLTPTWR
IHADQLTPTWRVYSTQLTPTWRVYSTGSNVTWRVYSTGSNVFQTRYSTGSNVFQTRAGCLSNVFQTRAGCLIGAEQTRAGCLIGAEYVNNGCLIGAEYVNNSYECGAEYVNNSYECDIPIVNNSYECDIPIGAGIYECDIPIGAGICASYIPIGAGICASYQTQTAGICASYQTQTKSHRASYQTQTKSHRRAR